2018 Innovator Under 35: Will McLean

Will McLean, Frequency Therapeutics

Hearing loss in humans has always been irreversible. His innovation may change that.

Will McLean, Cofounder and Vice President of Biology and Regenerative Medicine, Frequency Therapeutics

Will McLean studied biology as an undergraduate at Tufts University before going on to attain his PhD at the Massachusetts Institute of Technology within the Harvard-MIT Division of Health Sciences and Technology. His doctoral research elucidated the distinct progenitor cell types that exist within the inner ear and their capacity to form hearing and balance sensory cells and neural cell types. As a postdoctoral researcher at Harvard Medical School, Will investigated small-molecule manipulation of signaling pathways to enable otherwise senescent progenitor cells of the cochlea to divide and form new sensory cells. He is a cofounder and vice president of biology and regenerative medicine at Frequency Therapeutics. Frequency is currently using his insights to develop a drug to treat hearing loss by regenerating lost sensory cells.


Innovators Under 35
individuals whose superb technical work promises to shape the coming decades through the development of new technology or the creative application of existing technologies to solve problems.